View Cart  

Aug. 6, 2012

Vol. 9 No. 153

View Archived Issues

Sign Up Now

Alleged Fat-Melting Device Focus of Citizen Petition, Texas Scrutiny

A medical device alleged to melt cellulite should be removed from the market immediately because it poses a significant safety risk and was never cleared by the FDA, patient advocacy group Public Citizen says in a July 18 letter to the FDA. Read More

Australia’s TGA Moves Joint Implants to Highest-Risk Classification

Makers of hip, knee and shoulder joint implants have two years from July 1, 2012, to apply for their products to be transitioned from Class IIb to Class III devices in Australia, according to the Therapeutic Goods Administration (TGA). Read More

Acacia Subsidiary Acquires Patent on Intraluminal Device Technology

Acacia Research announced Friday that a subsidiary has acquired a patent for intraluminal device technology. Read More

Covidien Opens $45 Million Research Facility in Shanghai

Healthcare products company Covidien said today it has officially opened a new $45 million research and development facility in Shanghai, China. Read More

Medical College of Wisconsin to Study New Incontinence Device

The Medical College of Wisconsin has begun a clinical study of InTone, a new, FDA-approved medical device that treats female urinary incontinence. Read More

Defective Medical Devices Can Result in Complications, Medical Malpractice Claims

Patients should know their rights if they experience side effects from a medical device. Read More

Irish Passion Continues to Attract Boston Commitment

Boston Scientific has more than 4,500 employees in Ireland but fears that the company may be planning to reduce its footprint here are misplaced, said its CEO who trumpets the “stellar” performance of its Irish operations. Read More

Becton Dickinson 3Q Income Falls 4.7 Percent

Becton Dickinson said fiscal third-quarter income fell 4.7 percent and unfavorable currency rates will reduce its full-year earnings. Read More